Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Novelion Therapeutics Inc (NQ: NVLN )

0.6800 USD UNCHANGED
Last Price Updated: 4:35 PM EDT, Oct 8, 2019 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Novelion Therapeutics Inc

< Previous 1 2 Next >
Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases, today announced that clinical data... 
From GlobeNewswire News Releases
MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the European... 
From GlobeNewswire News Releases
Novelion Therapeutics Reports First Quarter 2018 Financial Results
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”),... 
From GlobeNewswire News Releases
Novelion Therapeutics Supports World Lipodystrophy Day
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today recognizes World Lipodystrophy Day. 
From GlobeNewswire News Releases
Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”),... 
From GlobeNewswire News Releases
Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital
Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital 
From GlobeNewswire News Releases
Novelion Therapeutics Observes Rare Disease Day
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases 
From GlobeNewswire News Releases
Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals
Financial terms of the sentence align with previous company filings 
From GlobeNewswire News Releases
Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review
Significant operating cost and workforce reductions estimated to lower operational expenses by approximately $18 million in 2018 
From GlobeNewswire News Releases
Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment... 
From GlobeNewswire News Releases
Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that District... 
From GlobeNewswire News Releases
Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing innovative new therapies for individuals living with rare diseases (“Novelion” or the... 
From GlobeNewswire News Releases
Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment... 
From GlobeNewswire News Releases
Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment... 
From GlobeNewswire News Releases
Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH... 
From GlobeNewswire News Releases
Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of two... 
From GlobeNewswire News Releases
Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Suzanne... 
From GlobeNewswire News Releases
Novelion Therapeutics Reports Second Quarter 2017 Financial Results
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing innovative new therapies for individuals living with rare and unmet need diseases... 
From GlobeNewswire News Releases
Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark... 
From GlobeNewswire News Releases
Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
Conference call and Webcast Scheduled for 8:30am ET 
From GlobeNewswire News Releases
Novelion Therapeutics Added to the Russell 3000® & Russell Microcap® Indexes
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that it has been added to... 
From GlobeNewswire News Releases
Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data... 
From GlobeNewswire News Releases
Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of John J.... 
From GlobeNewswire News Releases
Novelion Therapeutics Reports First Quarter 2017 Financial Results
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing innovative new therapies for individuals living with rare and unmet need diseases... 
From GlobeNewswire News Releases
Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the... 
From GlobeNewswire News Releases
Novelion Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
Conference call and Webcast Scheduled for 8:30am ET 
From GlobeNewswire News Releases
Novelion Therapeutics Announces Presentation at the Bloom Burton & Co. Healthcare Investor Conference
Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the... 
From GlobeNewswire News Releases
Novelion Therapeutics’ Request to Voluntarily Delist from the Toronto Stock Exchange Granted
Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that, as part... 
From GlobeNewswire News Releases
Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
Open-label study in patients with partial lipodystrophy-associated NASH featured in oral presentation 
From GlobeNewswire News Releases
Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors
Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment... 
From GlobeNewswire News Releases
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.